Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Model scores of the 29,894 trials active now.

Model score 41% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-05-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomacelland neckhead andsquamous
  Phrases that lowered it: patientspackpulmonaryallergicjoint
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.4% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.4% (raises risk) · Drug's FDA history
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 30994 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 5768 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for Intermediate Risk HPV-16-associated Head and Neck Squamous Cell Carcinoma NCT04369937 · started 2020 · scored riskier than 99% of active trials completed
• CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04633278 · started 2021 · scored riskier than 87% of active trials terminated
• A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer NCT01057589 · started 2010 · scored riskier than 69% of active trials completed
• A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) NCT02358031 · started 2015 · scored riskier than 28% of active trials completed
• Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer NCT02764593 · started 2016 · scored riskier than 77% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.